IE43726B1 - Improvements in or relating to soft drinks containing electrolytes - Google Patents
Improvements in or relating to soft drinks containing electrolytesInfo
- Publication number
- IE43726B1 IE43726B1 IE2096/76A IE209676A IE43726B1 IE 43726 B1 IE43726 B1 IE 43726B1 IE 2096/76 A IE2096/76 A IE 2096/76A IE 209676 A IE209676 A IE 209676A IE 43726 B1 IE43726 B1 IE 43726B1
- Authority
- IE
- Ireland
- Prior art keywords
- hypotonic
- water
- ions
- osmolarity
- sweetening agent
- Prior art date
Links
- 239000003792 electrolyte Substances 0.000 title description 25
- 235000014214 soft drink Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 235000003599 food sweetener Nutrition 0.000 claims description 17
- 239000003765 sweetening agent Substances 0.000 claims description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 9
- 229910001414 potassium ion Inorganic materials 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 8
- 229910001415 sodium ion Inorganic materials 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 4
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 4
- 239000008122 artificial sweetener Substances 0.000 claims description 4
- 229940085991 phosphate ion Drugs 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 230000030136 gastric emptying Effects 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 206010019332 Heat exhaustion Diseases 0.000 description 3
- 206010019345 Heat stroke Diseases 0.000 description 3
- 241001558496 Talpa caeca Species 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000021096 natural sweeteners Nutrition 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 241000207199 Citrus Species 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- 241000220223 Fragaria Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 208000025599 Heat Stress disease Diseases 0.000 description 2
- 206010019330 Heat cramps Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 239000009261 D 400 Substances 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000009378 Low Cardiac Output Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GSHUZVSNIBLGMR-UHFFFAOYSA-N calcium;1,1-dioxo-1,2-benzothiazol-3-one Chemical compound [Ca].C1=CC=C2C(=O)NS(=O)(=O)C2=C1 GSHUZVSNIBLGMR-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000005048 flame photometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019223 lemon-lime Nutrition 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000012232 skeletal muscle contraction Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Description
This invention relates to powdered mixtures which can be reconstituted with water to form electrolyte drinks. More specifically, this invention relates to flavored, powdered mixtures which can be reconstituted with water to form flavored hypotonic drinks which are characterised by rapid gastric emptying into the system thereby providing excellent availability of water and electrolytes to the system.
Such drinks are desirable for all individuals who have undergone exercise, strenuous work or activity but are particularly recommended for athletes engaged in all levels of athletic training and competition.
Athletes are particularly prone to exercise and heatrelated Illnesses, particularly those who are not In peak physical condition. The cause of such disorders may be traced directly to dehydration and loss of electrolytes from the body. During exercise or athletic competition, body activity greatly Increases, resulting in the production of heat. Only about 25$ of the energy generated is converted into useful work with the remaining 75$ evolved as body heat and 80-90$ of said body heat is dissipated by the evaporation of sweat.
Since body temperature regulation has priority over the maintenance of the water and salt balance, sweating will occur and continue in an effort to maintain normal body temperature and this can result in iehydration and marked electrolyte losses. The most -243736 Important electrolytes affected are the sodium, potassium, chloride and phosphate ions. It is not unusual for an athlete to lose about 5# of his body weight during two football practices occuring in a single day.
As a result of these effects on the body, three common exercise and heat-related disorders may occur; heat cramps, heat exhaustion and/or heat stroke. Heat cramps are characterized by painful skeletal muscle contractions and are the result of large sodium and chloride ion losses in both sweat and urine, and a possible potassium ion deficit.
Heat exhaustion occurs when losses of water and salts are high, resulting in a fall in the blood pressure, low cardiac output, and a high pulse rate due to the decrease in blood volume and extracellular fluid.
The reduction in circulation leads to a rise in body temperature as the dispersion of heat becomes more difficult. Cell metabolism is upset when large amounts of water and potassium ions are lost from the cells. This loss of water and potassium ions is critical since potassium is necessary for the maintenance of heart muscle and skeletal muscle fiber tone. Heat exhaustion symptoms include profuse sweating, lassitude or fatigue, vomiting and fainting; all of which can occur when weight losses are about 5# of body weight or greater.
Heat stroke is the most dangerous form of heat injury. It is the result of high body temperatures in the region of 1O5-1O6°F and is classified as a medical emergency. At these temperatures, the thermal regulatory mechanism in the brain breaks down due to cell damage -3437SS which may he permanent if the temperature is not reduced rapidly. Heat stroke symptoms include headache, weakness, vertigo, and dry skin... When the loss of body weight exceeds 10$, there is a good chance of circulatory collapse and death. Body temperatures must be reduced as fast as possible and fluids should be provided t intravenously and by mouth, if possible.
These and other physical disorders have long been recognized as possible highly undesirable effects of strenuous exercise or athletic competition and various methods of minimizing the dangers of such effects have been proposed including attaining the proper physical conditioning and utilizing the proper clothing and/or protective equipment. In recent years, the time-accepted tradition of not drinking large amounts of liquids to satisfy one's thirst during or immediately after strenuous activity has come under question and led to the introduction of various thirst quencher or so-called electrolyte drinks.
Such products have as their avowed purpose the resupply of water and electrolytes to the system. The products presently available have serious deficiencies in fully satisfying this purpose. For example, some products are formulated in a manner which prevents their emptying from the stomach into the bloodstream quickly while other formulations are unpalatable cr leave a bitter aftertaste which results in hindering rather than encouraging one to fully utilize such products and thus one does not obtain sufficient quantities of water and electrolytes to replace that which has been lost. -44 3 7 2 6 It is therefore a general, object of this invention to provide a dry mixture suitable for reconstituting with water into a drink which overcomes the abovediscussed negatives of the products that have previously been available to the consumer.
It is another object to provide a dry mixture suitable far reconstituting with water into a hypotonic drink characterized by fast gastric emptying resulting in rapid availability of water and electrolytes to the system.
It is a further object of the pi'esent· invention to provide a dry mixture suitable for reconstituting with water into a flavoured hypotonic drink with a relatively low level of sweetening agents and a satisfactory taste.
According' to the invention we provide a hypotonic drink winch comprises sodium ions, potassium ions, chloride ions and phosphate ions and a sweetening agent and has an osmolarity of from 60 to 200 mOsm.
The invention further provides a dry powdered mixture adapted by virtue of its composition for reconstituting with water to form a hypotonic drink comprising specific amounts of salt electrolytes and .sweetening agents and having tli<· specific osmolarity mentioned in tile preceding paragraph. - 5 43726 An important characteristic of the drinks of the present invention is the tonicity or, as it is often called, the osmolarity of said drinks. For the purposes of describing the present invention, these terms will be used interchangeably. Tonicity is a measure of the osmotic pressure of a solution relative to the osmotic pressure of the blood fluids. An isotonic solution is a solution of the same tonicity (osmotic pressure) as a normal saline solution and therefore is of the same tonicity as blood serum. A hypertonic solution is a solution of greater tonicity than an isotonic solution whereas a hypotonic solution is a solution of lower tonicity than an isotonic solution. It has unexpectedly now been found that the tonicity of electrolyte drinks is particularly critical with respect to providing rapid gastric emptying of the solution from the stomach into the bloodstream. Thus, it appears that the tonicity (osmolarity) of any drink solution is directly related to the rate at which Such a solution can get from the stomach into the bloodstream. Most commercially available electrolyte drinks are either isotonic or hypertonic and tend to empty relatively slowly from the stomach. Aside from the slower availability of the needed water and electrolytes to the system, the slower emptying from the stomach also results in more -64 3720 fluid remaining in the stomach of the individual who has to rehydrate rapidly and this discourages the intake of additional fluid resulting in less of the needed water and electrolytes getting into the system to replace what has been lost as a result of sweating.
We have now unexpectedly found that an osmolarity of from So to 200 mOsm per liter is required in order to provide emptying of the solutions from the stomach into the bloodstream in a rapid manner to provide the needed electrolytes and water to the system.
A preferred osmolarity is from 90 to IJO iiiOsm.
Most commercially available products have osmolalities significantly higher than the above levels.
It has now been found that by controlling the amount of electrolytes that are included in the mixtures of the present invention and by limiting the amounts of sweetening agents added to such mixtures, the osmolarity of the resulting solutions can be maintained within the desirable levels thereby resulting in fast gastric emptying and rapid availability of water and electrolytes to the system. It has also been found that by utilizing lower than normally suggested levels of sweetening agents in such mixtures, the osmolarity of the resulting solutions can be regulated such that the gastric emptying rate is not adversely affected although a pleasantly tasting, non-bitter drink is still provided.
The dry mixtures of the present invention suitable for reconstitution with water should contain sodium) potassium, chloride and phosphate ions as electrolytes in amounts sufficient to provide adequate -7replacement of the normal levels of these components in the body as well as a specific amount of suitable sweetening agents, optional.ly with citric acid, suitable flavorings and coloring agents. The sodium and potassium salts useful In this invention can be, for example, chlorides, citrates, or phosphates, although it would he desirable for at least some of these salts to he the chlorides and phosphates since such would provide the chloride and phosphate ions in addition to supplying the sodium and potassium ions.
In order to satisfy the objectives of the present invention, it is necessary for the electrolytes to he present in specific amounts. The sodium ion should be present in a range of from 10 to aEq par liter, the potassium ion in a range of from 0.5 to 20 mEq per liter, the chloride ion in a range of from io to 35 niliq per I iter and the phosphate ion in a range of from 1 to mEq per liter. Problems may develop 1Γ amounts of these electrolytes outside the ranges are utilized, I for example, if too much sodium ion content is present in the dry mixture, the resultant solution may have a. salty taste and may cause some stomach irritation. If too much chloride ion or phosphate ion is present in the dry mixture, the resultant solutions may have flavor problems, The sweetening agents which can. be utilized in the present invention include both the natural and artificial sweeteners. The natural sweeteners Include sugars such as glucose, sucrose, lactose, and maltose. The total concentration -8A 3 726 of the natural sweeteners should he from l to 54 m. moles (millimoies) per liter since if amounts greater than 54 m. moles per liter are utilized the osmolarity would be adversely affected. Thus, for example, the glucose can be utilized in a range of from 0 to g. per liter and the sucrose in a range of from to 20 g. per liter as long as the total concentration is not greater than 54 m. moles per liter.
Part of the natural sweetening agents can be replaced by artificial sweetening agents such as the saccharins, cyclamates where permitted, dipeptides such as the dipeptide sold under the trademark Aspartame by G. D. Searle & Company. Specifically, sodium or calcium saccharin can be substituted for some of the natural sweetening agents to provide the desired sweetness without adversely affecting the osmolarity although use of too much of the artificial sweetening agents may cause flavor problems to the resulting drink.
It should be borne in mind that choosing the amounts of the above ingredients to be utilized requires a balancing of the desired features to be achieved.
For example, in order to keep the osmolarity within the specific range to achieve rapid gastric emptying into the system, the amount of sweetening agents must be limited and yet sufficient amounts must be utilized to provide a pleasant tasting drink in order to encourage its use. Thus, if excess chloride or phosphate Ion is utilized, flavor problems may result requiring additional sweetening agents which may adversely affect the osmolarity. -9Therefore, the amounts of the required, components of the mixtures of the present invention must be carefully maintained within the above limitations to achieve the desired results of the present invention.
Other components which can be utilized in the mixtures and drinks' of the present invention include such components as ar,e normally found in such compositions such as citric acid or the salts thereof, ascorbic acid, j flavors, colorings. The citric acid can be present in the range of from 0 -10 £. per liter and is utilized as an aid to develop the flavor of the mixture and resultant drink. Ascorbic acid provides a source of Vitamin C which is desirable. Flavors such as the citrus flavors, for example, orange, lemon, lemon-lime and the non-citrus flavors, for example, strawberry, punch and colorings such as United States FD&C Red ΐρ 40 and FD&C Yellow^S, can be utilized, where permitted to achieve the desired flavor and colors of the resulting drink.
The mixtures of the present invention can be prepared by conventional mixing and blending techniques utilizing standard equipment. The components are milled to a suitable size and then mixed and blended in the required amounts to form the mixtures which can then be reconstituted with water as desired.
S 7 Z Q EXAMPLE I An orange flavored, powdered mixture in accordance with the present invention was prepared by milling the components through a No. 4 screen (h.S. Standard) and then blending the components for about 10 minutes in an ABBE blender to obtain a dry powdered mi xture of the fel l owi ng composition: % w/w Potassium chloride, granular 1.395 Sodium chloride, granular Potassium phosphate, (monobasic) 4.736 crystals 5.760 Sodium citrate, anhyd. powder 3.799 Sodium saccharin, powder 1.246 Ascorbic acid, granular 0.411 Glucose, USP, anhyd. 32.104 Sucrose, USP crystals 32.104 Citric acid, anhyd, gran. 15.570 FD&C Red No. 40 0.037 FD&C Yellow No. 5 0.037 Orange Flavor 2.801 EXAMPLE II A punch flavored, powdered mixture was prepared in accordance with the procedure of Example I and was of the following composition: $ W/W Potassium chloride, granular Sodium chloride, granular Potassium phosphate,(monobasic) crystals Sodium citrate, anhyd. powder FGC Sodium saccharin, powder Ascorbic acid, granular Glucose, USP, anhyd.
Sucrose, USP crystals Citric acid, anhyd. gran. Strawberry Flavor Punch Flavor FD&C Red Uo. 40 1.355 4.599 .598 3.691 1.210 0.400 31.195 31.195 18.155 1.210 1.210 0.182 62.5 grams of this mixture is reconstituted with one u.s. gallon of water to form a pleasantly tasting punch-flavored hypotonic tonic.
EXAMPLE III The composition of Example I and four commercially available thirst quencher drinks designated as A, B, . t C and D were reconstituted according to instructions.
These drinks were then analyzed for sodium and potassium ion contents by means of flame photometry and for chloride Ion content by means of potentiometric titration. The natural sweetening agent content was determined by standard glucose oxidation methods and the osmolarity sf each of the solutions was determined by a depression sf freezing point method. The results of these analyses ire shown in Table I below: -1243726 TABLE I Natural Sweetening Solution Na+ (®sqA)..... K+ (mEq/l) Cl- . (mEq/l) Osm (m0sm/l) Agent (g/lOOml) A 26.3 0.6 21.5 294 4.1 B 15.3 8.4 17.0 281 4.9 C 26.3 2.4 16.0 319 6.6 D 17.5 1.4 17.0 258 4.7 Ξ 23.0 9.3 14.8 118 1.3 As can readily be observed from the above results, although other compositions provide similar amounts of sodium,· potassium and chloride ions, only solution E, the composition of Example I made up as a hypotonic drink provides a low sugar concentration and an osmolarity in the desired range in order to provide the desired rapid gastric emptying of the solution resulting in the fast availability of water and electrolytes to the system.
EXAMPLE IV In order to demonstrate the rapid gastric emptying of the solutions of the present invention resulting in the fast availability of water and electrolytes to the system, the following test was conducted. Six men ingested 4oo ml. of the solutions Of Example III 400 ml. of water and the gastric residue was measured by means of inserting a tube into the stomach and withdrawing the fluid therein 15 minutes later to determine the volume emptied from the stomach. The results are reported in Table II below: -1343726 Solution TABLE II Volume Ingested (ml) Gastric Residue (ml) Volume Emptied from Stomach (ml) A 400 301 99 B 400 275 125 C 4oo 263 137 D 400 267 133 E 4oo 125 275 Water 4oo 187 213 As can readily be seen from the results above, the solution of Example I of the present invention empties significantly faster than the commercially available electrolyte drink solutions A, B, C and D tested above and even more than water alone. It would thus be apparent that the solutions of the present invention unexpectedly provide water and electrolytes to the system more rapidly than previously available products which is, as discussed above, highly desifable.
Claims (7)
1. CLAIMS:1A hypotonic drink which comprises sodium ions, potassium ions, chloride ions and phosphate ions and a sweetening agent and has an osmolarity of from 80 to 200 mOsm 5.
2. A hypotonic drink according to Claim 1, wherein the sodium ion content is from 10 to 35 niKti per litre, tho potassium ion content is from 0.5 to 20 niliq per litre, the chloride ion content is from 10 to 35 mEq per litre, the phosphate ion content is from 1 to 15 mEq per litre, and the 10 sweetening agent is present in a concentration of from 1 to 54 millimoles per litre.
3. A hypotonic drink according to Claim 1 or 2, wherein the sweetening agent is a natural sweetening agent selected from sucrose, glucose or a mixture thereof. 15
4. · Λ hypotonic drink according to Claim 3, wherein the natural sweetening agent is partly replaced by an artificial sweetener.
5. A hypotonic drink according to any preceding Claim, wherein the osmolarity is from 90 to 130 mOsm. 20
6. A hypotonic drink according to Claim 1, substantially as described in the foregoing Examples.
7. A dry powdered mixture adapted by virtue of its composition for reconstituting with water to form a hypotonic drink as claimed in any of Claims 2 to 6. 25 8, A mixture according to Claim 7, substantially as described in the foregoing Examples.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61533875A | 1975-09-23 | 1975-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE43726L IE43726L (en) | 1977-03-23 |
IE43726B1 true IE43726B1 (en) | 1981-05-06 |
Family
ID=24464931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE2096/76A IE43726B1 (en) | 1975-09-23 | 1976-09-22 | Improvements in or relating to soft drinks containing electrolytes |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPS5241273A (en) |
AU (1) | AU1796976A (en) |
BE (1) | BE846462A (en) |
DE (1) | DE2642632A1 (en) |
DK (1) | DK427776A (en) |
FI (1) | FI762700A (en) |
FR (1) | FR2325330A1 (en) |
GB (1) | GB1541461A (en) |
IE (1) | IE43726B1 (en) |
IT (1) | IT1066179B (en) |
NL (1) | NL7610539A (en) |
NO (1) | NO763227L (en) |
NZ (1) | NZ182117A (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54154569A (en) * | 1978-05-20 | 1979-12-05 | Lotte Co Ltd | Chewing gum for sports |
US4309417A (en) * | 1980-07-10 | 1982-01-05 | Stauffer Chemical Company | Protein fortified isotonic beverages |
CH634203A5 (en) * | 1982-01-12 | 1983-01-31 | Haigis Erich Mathias | DRINK FOR PEOPLE AND ANIMALS. |
AU571011B2 (en) * | 1983-10-07 | 1988-03-31 | State Of Victoria, The | Treatment of neonatal calf diarrhoea |
CH644737A5 (en) * | 1983-10-10 | 1984-08-31 | Baltensperger E Natrex Diaetet | DRINK WITH A HIGH MAGNESIUM CONTENT. |
DE3444086A1 (en) * | 1984-12-04 | 1986-06-12 | Hans Dr. 8202 Bad Aibling Dietl | Electrolyte drink for the replacement of minerals |
SE468074B (en) * | 1985-11-22 | 1992-11-02 | Medina Hb | PREPARATION FOR IMPROVING CELLULAR METABOLISM |
NL8802525A (en) * | 1988-10-13 | 1990-05-01 | Dmv Campina Bv | PROCESS FOR PREPARING HYPOTONE OR ISOTONE DRINKS. |
US5114723A (en) * | 1990-02-27 | 1992-05-19 | University Of Texas System Board Of Regents | Beverage compositions for human consumption |
GB9819530D0 (en) | 1998-09-09 | 1998-10-28 | Smithkline Beecham Plc | Novel compositions and use |
JP2001112867A (en) | 1999-10-18 | 2001-04-24 | Terumo Corp | Syringe containing drug |
US9585827B2 (en) * | 2000-01-21 | 2017-03-07 | The Procter & Gamble Company | Kits comprising a beverage composition and information for use |
JP4811576B2 (en) * | 2005-03-31 | 2011-11-09 | 味の素株式会社 | Moisture electrolyte supplement drink |
US9131727B2 (en) | 2008-07-16 | 2015-09-15 | Kraft Foods Group Brands Llc | Milk acidification composition for powdered beverage |
EP2345337B1 (en) * | 2008-10-28 | 2016-06-01 | Otsuka Pharmaceutical Co., Ltd. | Low-calorie beverage composition containing luo han guo extract and sucralose |
JP2012065617A (en) * | 2010-09-24 | 2012-04-05 | Hitoshi Ishida | Alcoholic beverage and wort beverage with effect of preventing dehydration |
WO2013133442A1 (en) * | 2012-03-09 | 2013-09-12 | 株式会社明治 | Food or beverage that allows high degree of absorption of water |
JP2017523231A (en) * | 2014-08-15 | 2017-08-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Afatinib drug kit for cancer treatment |
-
1976
- 1976-09-21 AU AU17969/76A patent/AU1796976A/en not_active Expired
- 1976-09-21 NO NO763227A patent/NO763227L/en unknown
- 1976-09-21 NZ NZ182117A patent/NZ182117A/en unknown
- 1976-09-22 BE BE170840A patent/BE846462A/en unknown
- 1976-09-22 GB GB39277/76A patent/GB1541461A/en not_active Expired
- 1976-09-22 IT IT51394/76A patent/IT1066179B/en active
- 1976-09-22 JP JP51113169A patent/JPS5241273A/en active Pending
- 1976-09-22 DE DE19762642632 patent/DE2642632A1/en not_active Withdrawn
- 1976-09-22 DK DK427776A patent/DK427776A/en unknown
- 1976-09-22 IE IE2096/76A patent/IE43726B1/en unknown
- 1976-09-22 FI FI762700A patent/FI762700A/fi not_active Application Discontinuation
- 1976-09-22 NL NL7610539A patent/NL7610539A/en not_active Application Discontinuation
- 1976-09-23 FR FR7628612A patent/FR2325330A1/en active Granted
Also Published As
Publication number | Publication date |
---|---|
BE846462A (en) | 1977-03-22 |
NL7610539A (en) | 1977-03-25 |
IT1066179B (en) | 1985-03-04 |
FR2325330A1 (en) | 1977-04-22 |
NZ182117A (en) | 1978-07-28 |
FI762700A (en) | 1977-03-24 |
JPS5241273A (en) | 1977-03-30 |
AU1796976A (en) | 1978-04-06 |
NO763227L (en) | 1977-03-24 |
IE43726L (en) | 1977-03-23 |
DK427776A (en) | 1977-03-24 |
FR2325330B3 (en) | 1979-06-01 |
DE2642632A1 (en) | 1977-03-24 |
GB1541461A (en) | 1979-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE43726B1 (en) | Improvements in or relating to soft drinks containing electrolytes | |
Saat et al. | Rehydration after exercise with fresh young coconut water, carbohydrate-electrolyte beverage and plain water | |
US4312856A (en) | Beverage product | |
Atkin-Thor et al. | Hypogeusia and zinc depletion in chronic dialysis patients | |
AU733474B2 (en) | Improvements in or relating to compositions containing creatine | |
US4322407A (en) | Electrolyte drink | |
US5780094A (en) | Sports drink | |
US6761912B2 (en) | Composition for increasing bone density | |
KR100759147B1 (en) | Compositions containing creatine in suspension | |
US4448770A (en) | Dietetic beverage | |
PT1382263E (en) | Use of calcium in acidic oral compositions for the reduction of tooth erosion caused by acid | |
JP2009062370A (en) | Solid composition for reducing tooth erosion | |
US6168802B1 (en) | Compositions containing creatine and aloe vera extract | |
US6485764B2 (en) | Hydrating beverages and method | |
EP0573466A1 (en) | Dietetic or pharmaceutical compositions for the restoration of adenine nucleotide cell content in skeletal and cardiac muscles. | |
Nelson et al. | Fluid and electrolyte balance during a cool weather marathon | |
Greenleaf | Environmental issues that influence intake of replacement beverages | |
Froehlich et al. | Palatability of a new solution compared with standard polyethylene glycol solution for gastrointestinal lavage | |
US20050100636A1 (en) | [A Low-Calorie Sports Drink For Physically Active Women That is Fortified with Iron, Calcium and Essential Vitamins for Use in Rehydration and Replacing Electrolytes Lost During Periods of Physical Activity] | |
EP0181988A1 (en) | Beverage Product | |
Spencer et al. | Availability of fluoride from fish protein concentrate and from sodium fluoride in man | |
US20100298242A1 (en) | Masking the taste of compositons containing salt | |
GB2356788A (en) | Trehalose for use in exercise | |
RU2134241C1 (en) | Artificial mineralized water and composition for producing it | |
EP0634110A2 (en) | Fluid food |